12:21 PM
 | 
Oct 20, 2017
 |  BC Week In Review  |  Company News  |  Deals

HemoShear, Takeda in liver disease deal

HemoShear Therapeutics LLC (Charlottesville, Va.) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered to discover and develop therapeutics for liver diseases including non-alcoholic steatohepatitis (NASH). HemoShear will receive undisclosed upfront payments and R&D funding and is eligible for $470 million in milestones, plus royalties.

HemoShear Head of Innovation Brian Wamhoff told BioCentury the partnership has three aims -- to...

Read the full 272 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >